Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

Summary

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.

Timeline

Start

2020-11-09

Primary completion

2022-02-09

Completion

2022-02-18

Outcome

Missed primary endpoint

registry analysis (superiority test); ETX-018810 vs Placebo; p = 0.5605; Mean Difference (Final Values) 0.18 (90% CI -0.32 to 0.68); Mixed Models Analysis NCT04688671 ↗

Drugs

Indications